BIOLOGICS HQ

Spotlight On:

Etanercept

VENABLE | Fitzpatrick

December 31, 2019

Technology: Etanercept is a recombinant tumor necrosis factor receptor ("TNFR"):F_c fusion protein that is indicated for the treatment of various types of arthritis, ankylosing spondylitis, and plaque psoriasis.

Etanercept Claims Challenged in IPR and Litigation*



VENABLE | Fitzpatrick

*Litigation Defendants alleged to infringe at least these claims in complaints/amended complaints.

Etanercept Timeline



VENABLE | Fitzpatrick

	Sandoz v. Amgen 3:13-cv-02904 (N.D. Cal.) Dismissed for lack of subject matter jurisdiction; Fed. Cir. 14-1693 Affirmed	*Amgen v. Sandoz* 2:16-cv-01118 (D.N.J.) Patents not invalid; Stipulation of infringement	*Amgen v. Samsung Bioepis* 2:19-cv-11755 (D.N.J.) Ongoing	*Coalition for Affordable Drugs v. Amgen* IPR2015-01792 Institution denied	*Coherus v. Hoffman-La Roche* IPR2017-01916 Institution denied	*Coherus v. Hoffman-La Roche* IPR2017-02066 Institution denied
7,915,225		x	x			
8,063,182	x	x	x			x
8,119,605		x	x			
8,163,522	x	x	x	x	x	
8,722,631		x	x			